http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Fri, 20 Feb 2026 16:22:00 -0500 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++ATOSSA+THERAPEUTICS%2C++++++For%3A+Feb+19/26036392.html si-local-file:///var/storage/secattach/20260220/26036392.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++ATOSSA+THERAPEUTICS%2C++++++For%3A+Feb+19/26036392.html Fri, 20 Feb 2026 16:22:00 -0500 ATOS O.11433789 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++ATOSSA+THERAPEUTICS%2C++++++For%3A+Feb+19/26036392.html si-local-file:///var/storage/secattach/20260220/26036392.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++ATOSSA+THERAPEUTICS%2C++++++For%3A+Feb+19/26036392.html Fri, 20 Feb 2026 16:22:00 -0500 ATOS O.11433789 http://www.streetinsider.com/SEC+Filings/Form++424B5++++++ATOSSA+THERAPEUTICS%2C+++++++++++++++++/26036269.html si-local-file:///var/storage/secattach/20260220/26036269.html http://www.streetinsider.com/SEC+Filings/Form++424B5++++++ATOSSA+THERAPEUTICS%2C+++++++++++++++++/26036269.html Fri, 20 Feb 2026 16:16:00 -0500 ATOS O.11433789 http://www.streetinsider.com/SEC+Filings/Form++424B5++++++ATOSSA+THERAPEUTICS%2C+++++++++++++++++/26036269.html si-local-file:///var/storage/secattach/20260220/26036269.html http://www.streetinsider.com/SEC+Filings/Form++424B5++++++ATOSSA+THERAPEUTICS%2C+++++++++++++++++/26036269.html Fri, 20 Feb 2026 16:16:00 -0500 ATOS O.11433789 http://www.streetinsider.com/SEC+Filings/Form++424B3++++++ATOSSA+THERAPEUTICS%2C+++++++++++++++++/26036045.html si-local-file:///var/storage/secattach/20260220/26036045.html http://www.streetinsider.com/SEC+Filings/Form++424B3++++++ATOSSA+THERAPEUTICS%2C+++++++++++++++++/26036045.html Fri, 20 Feb 2026 16:07:00 -0500 ATOS O.11433789 http://www.streetinsider.com/SEC+Filings/Form++424B3++++++ATOSSA+THERAPEUTICS%2C+++++++++++++++++/26036045.html si-local-file:///var/storage/secattach/20260220/26036045.html http://www.streetinsider.com/SEC+Filings/Form++424B3++++++ATOSSA+THERAPEUTICS%2C+++++++++++++++++/26036045.html Fri, 20 Feb 2026 16:07:00 -0500 ATOS O.11433789 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++ATOSSA+THERAPEUTICS%2C++++++For%3A+Feb+17/26013829.html si-local-file:///var/storage/secattach/20260217/26013829.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++ATOSSA+THERAPEUTICS%2C++++++For%3A+Feb+17/26013829.html Tue, 17 Feb 2026 16:32:00 -0500 ATOS O.11433789 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++ATOSSA+THERAPEUTICS%2C++++++For%3A+Feb+17/26013829.html si-local-file:///var/storage/secattach/20260217/26013829.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++ATOSSA+THERAPEUTICS%2C++++++For%3A+Feb+17/26013829.html Tue, 17 Feb 2026 16:32:00 -0500 ATOS O.11433789 http://www.streetinsider.com/Analyst+PT+Change/Atossa+Genetics+%28ATOS%29+PT+Lowered+to+%2410+at+Craig-Hallum/25988149.html Craig-Hallum analyst Albert Lowe lowered the price target on Atossa Genetics (NASDAQ: ATOS) to $10.00 (from $35.00) while maintaining a Buy rating. http://www.streetinsider.com/Analyst+PT+Change/Atossa+Genetics+%28ATOS%29+PT+Lowered+to+%2410+at+Craig-Hallum/25988149.html Thu, 12 Feb 2026 08:52:49 -0500 ATOS http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++ATOSSA+THERAPEUTICS%2C++++++For%3A+Feb+11/25980189.html si-local-file:///var/storage/secattach/20260211/25980189.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++ATOSSA+THERAPEUTICS%2C++++++For%3A+Feb+11/25980189.html Wed, 11 Feb 2026 08:46:00 -0500 ATOS O.11433789 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++ATOSSA+THERAPEUTICS%2C++++++For%3A+Feb+11/25980189.html si-local-file:///var/storage/secattach/20260211/25980189.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++ATOSSA+THERAPEUTICS%2C++++++For%3A+Feb+11/25980189.html Wed, 11 Feb 2026 08:46:00 -0500 ATOS O.11433789 http://www.streetinsider.com/Guidance/Atossa+Therapeutics+outlines+2025+progress+and+2026+plans+for+drug+development/25980029.html <p>Atossa Therapeutics Inc. (NASDAQ: ATOS) issued a shareholder letter detailing progress made in 2025 and outlining priorities for 2026, according to a company statement.</p><p>The clinical-stage biopharmaceutical company reported completing a Type C meeting with the U.S. Food and Drug Administration on November 17, 2025, regarding regulatory strategy for advancing (Z)-endoxifen in breast cancer treatment. The FDA provided feedback on potential expedited pathways and development options spanning metastatic disease, neoadjuvant treatment, and risk-reduction settings.</p><p>The company received two FDA designations for (Z)-endoxifen in treating Duchenne Muscular Dystrophy (DMD) in December 2025 and early 2026: Rare Pediatric Disease Designation and Orphan Drug Designation. http://www.streetinsider.com/Guidance/Atossa+Therapeutics+outlines+2025+progress+and+2026+plans+for+drug+development/25980029.html Wed, 11 Feb 2026 08:31:11 -0500 ATOS http://www.streetinsider.com/Corporate+News/Atossa+Therapeutics+outlines+2025+progress+and+2026+plans+for+drug+development/25980029.html <p>Atossa Therapeutics Inc. (NASDAQ: ATOS) issued a shareholder letter detailing progress made in 2025 and outlining priorities for 2026, according to a company statement.</p><p>The clinical-stage biopharmaceutical company reported completing a Type C meeting with the U.S. Food and Drug Administration on November 17, 2025, regarding regulatory strategy for advancing (Z)-endoxifen in breast cancer treatment. The FDA provided feedback on potential expedited pathways and development options spanning metastatic disease, neoadjuvant treatment, and risk-reduction settings.</p><p>The company received two FDA designations for (Z)-endoxifen in treating Duchenne Muscular Dystrophy (DMD) in December 2025 and early 2026: Rare Pediatric Disease Designation and Orphan Drug Designation. http://www.streetinsider.com/Corporate+News/Atossa+Therapeutics+outlines+2025+progress+and+2026+plans+for+drug+development/25980029.html Wed, 11 Feb 2026 08:31:11 -0500 ATOS http://www.streetinsider.com/Press+Releases/Atossa+Therapeutics+Issues+Letter+to+Shareholders+Highlighting+2025+Accomplishments+and+2026+Outlook/25980012.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.wa.seatle" idsrc="xmltag.org" >SEATTLE</location></span>, <span class="legendSpanClass"><chron>Feb. 11, 2026</chron></span> /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other areas of high unmet need, today issued a letter to Shareholders from <person value="APIN:0654458887">Steven Quay</person>, M.D., Ph.D., <span value="NASDAQ-SMALL:ATOS" idsrc="xmltag.org" >Atossa Therapeutics</span> President and Chief Executive Officer, providing an update on the Company's clinical programs and recent events. The full text of the letter follows:</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/Press+Releases/Atossa+Therapeutics+Issues+Letter+to+Shareholders+Highlighting+2025+Accomplishments+and+2026+Outlook/25980012.html Wed, 11 Feb 2026 08:30:00 -0500 A.01908724 A.06822034 A.07309385 A.18254799 ATOS O.01259980 O.11433789 O.20026344 O.20043539 O.20988509 http://www.streetinsider.com/Press+Releases/Atossa+Therapeutics+Issues+Letter+to+Shareholders+Highlighting+2025+Accomplishments+and+2026+Outlook/25980012.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.wa.seatle" idsrc="xmltag.org" >SEATTLE</location></span>, <span class="legendSpanClass"><chron>Feb. 11, 2026</chron></span> /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other areas of high unmet need, today issued a letter to Shareholders from <person value="APIN:0654458887">Steven Quay</person>, M.D., Ph.D., <span value="NASDAQ-SMALL:ATOS" idsrc="xmltag.org" >Atossa Therapeutics</span> President and Chief Executive Officer, providing an update on the Company's clinical programs and recent events. The full text of the letter follows:</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/Press+Releases/Atossa+Therapeutics+Issues+Letter+to+Shareholders+Highlighting+2025+Accomplishments+and+2026+Outlook/25980012.html Wed, 11 Feb 2026 08:30:00 -0500 A.01908724 A.06822034 A.07309385 A.18254799 ATOS O.01259980 O.11433789 O.20026344 O.20043539 O.20988509 http://www.streetinsider.com/Press+Releases/Atossa+Therapeutics+Issues+Letter+to+Shareholders+Highlighting+2025+Accomplishments+and+2026+Outlook/25980012.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.wa.seatle" idsrc="xmltag.org" >SEATTLE</location></span>, <span class="legendSpanClass"><chron>Feb. 11, 2026</chron></span> /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other areas of high unmet need, today issued a letter to Shareholders from <person value="APIN:0654458887">Steven Quay</person>, M.D., Ph.D., <span value="NASDAQ-SMALL:ATOS" idsrc="xmltag.org" >Atossa Therapeutics</span> President and Chief Executive Officer, providing an update on the Company's clinical programs and recent events. The full text of the letter follows:</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/Press+Releases/Atossa+Therapeutics+Issues+Letter+to+Shareholders+Highlighting+2025+Accomplishments+and+2026+Outlook/25980012.html Wed, 11 Feb 2026 08:30:00 -0500 A.01908724 A.06822034 A.07309385 A.18254799 ATOS O.01259980 O.11433789 O.20026344 O.20043539 O.20988509 http://www.streetinsider.com/Press+Releases/Atossa+Therapeutics+Issues+Letter+to+Shareholders+Highlighting+2025+Accomplishments+and+2026+Outlook/25980012.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.wa.seatle" idsrc="xmltag.org" >SEATTLE</location></span>, <span class="legendSpanClass"><chron>Feb. 11, 2026</chron></span> /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other areas of high unmet need, today issued a letter to Shareholders from <person value="APIN:0654458887">Steven Quay</person>, M.D., Ph.D., <span value="NASDAQ-SMALL:ATOS" idsrc="xmltag.org" >Atossa Therapeutics</span> President and Chief Executive Officer, providing an update on the Company's clinical programs and recent events. The full text of the letter follows:</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/Press+Releases/Atossa+Therapeutics+Issues+Letter+to+Shareholders+Highlighting+2025+Accomplishments+and+2026+Outlook/25980012.html Wed, 11 Feb 2026 08:30:00 -0500 A.01908724 A.06822034 A.07309385 A.18254799 ATOS O.01259980 O.11433789 O.20026344 O.20043539 O.20988509 http://www.streetinsider.com/Press+Releases/Atossa+Therapeutics+Issues+Letter+to+Shareholders+Highlighting+2025+Accomplishments+and+2026+Outlook/25980012.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.wa.seatle" idsrc="xmltag.org" >SEATTLE</location></span>, <span class="legendSpanClass"><chron>Feb. 11, 2026</chron></span> /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other areas of high unmet need, today issued a letter to Shareholders from <person value="APIN:0654458887">Steven Quay</person>, M.D., Ph.D., <span value="NASDAQ-SMALL:ATOS" idsrc="xmltag.org" >Atossa Therapeutics</span> President and Chief Executive Officer, providing an update on the Company's clinical programs and recent events. The full text of the letter follows:</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/Press+Releases/Atossa+Therapeutics+Issues+Letter+to+Shareholders+Highlighting+2025+Accomplishments+and+2026+Outlook/25980012.html Wed, 11 Feb 2026 08:30:00 -0500 A.01908724 A.06822034 A.07309385 A.18254799 ATOS O.01259980 O.11433789 O.20026344 O.20043539 O.20988509 http://www.streetinsider.com/Press+Releases/Atossa+Therapeutics+Issues+Letter+to+Shareholders+Highlighting+2025+Accomplishments+and+2026+Outlook/25980012.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.wa.seatle" idsrc="xmltag.org" >SEATTLE</location></span>, <span class="legendSpanClass"><chron>Feb. 11, 2026</chron></span> /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other areas of high unmet need, today issued a letter to Shareholders from <person value="APIN:0654458887">Steven Quay</person>, M.D., Ph.D., <span value="NASDAQ-SMALL:ATOS" idsrc="xmltag.org" >Atossa Therapeutics</span> President and Chief Executive Officer, providing an update on the Company's clinical programs and recent events. The full text of the letter follows:</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/Press+Releases/Atossa+Therapeutics+Issues+Letter+to+Shareholders+Highlighting+2025+Accomplishments+and+2026+Outlook/25980012.html Wed, 11 Feb 2026 08:30:00 -0500 A.01908724 A.06822034 A.07309385 A.18254799 ATOS O.01259980 O.11433789 O.20026344 O.20043539 O.20988509 http://www.streetinsider.com/Press+Releases/Atossa+Therapeutics+Issues+Letter+to+Shareholders+Highlighting+2025+Accomplishments+and+2026+Outlook/25980012.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.wa.seatle" idsrc="xmltag.org" >SEATTLE</location></span>, <span class="legendSpanClass"><chron>Feb. 11, 2026</chron></span> /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other areas of high unmet need, today issued a letter to Shareholders from <person value="APIN:0654458887">Steven Quay</person>, M.D., Ph.D., <span value="NASDAQ-SMALL:ATOS" idsrc="xmltag.org" >Atossa Therapeutics</span> President and Chief Executive Officer, providing an update on the Company's clinical programs and recent events. The full text of the letter follows:</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/Press+Releases/Atossa+Therapeutics+Issues+Letter+to+Shareholders+Highlighting+2025+Accomplishments+and+2026+Outlook/25980012.html Wed, 11 Feb 2026 08:30:00 -0500 A.01908724 A.06822034 A.07309385 A.18254799 ATOS O.01259980 O.11433789 O.20026344 O.20043539 O.20988509 http://www.streetinsider.com/Press+Releases/Atossa+Therapeutics+Issues+Letter+to+Shareholders+Highlighting+2025+Accomplishments+and+2026+Outlook/25980012.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.wa.seatle" idsrc="xmltag.org" >SEATTLE</location></span>, <span class="legendSpanClass"><chron>Feb. 11, 2026</chron></span> /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other areas of high unmet need, today issued a letter to Shareholders from <person value="APIN:0654458887">Steven Quay</person>, M.D., Ph.D., <span value="NASDAQ-SMALL:ATOS" idsrc="xmltag.org" >Atossa Therapeutics</span> President and Chief Executive Officer, providing an update on the Company's clinical programs and recent events. The full text of the letter follows:</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/Press+Releases/Atossa+Therapeutics+Issues+Letter+to+Shareholders+Highlighting+2025+Accomplishments+and+2026+Outlook/25980012.html Wed, 11 Feb 2026 08:30:00 -0500 A.01908724 A.06822034 A.07309385 A.18254799 ATOS O.01259980 O.11433789 O.20026344 O.20043539 O.20988509 http://www.streetinsider.com/Press+Releases/Atossa+Therapeutics+Issues+Letter+to+Shareholders+Highlighting+2025+Accomplishments+and+2026+Outlook/25980012.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.wa.seatle" idsrc="xmltag.org" >SEATTLE</location></span>, <span class="legendSpanClass"><chron>Feb. 11, 2026</chron></span> /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other areas of high unmet need, today issued a letter to Shareholders from <person value="APIN:0654458887">Steven Quay</person>, M.D., Ph.D., <span value="NASDAQ-SMALL:ATOS" idsrc="xmltag.org" >Atossa Therapeutics</span> President and Chief Executive Officer, providing an update on the Company's clinical programs and recent events. The full text of the letter follows:</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/Press+Releases/Atossa+Therapeutics+Issues+Letter+to+Shareholders+Highlighting+2025+Accomplishments+and+2026+Outlook/25980012.html Wed, 11 Feb 2026 08:30:00 -0500 A.01908724 A.06822034 A.07309385 A.18254799 ATOS O.01259980 O.11433789 O.20026344 O.20043539 O.20988509 http://www.streetinsider.com/Press+Releases/Atossa+Therapeutics+Issues+Letter+to+Shareholders+Highlighting+2025+Accomplishments+and+2026+Outlook/25980012.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.wa.seatle" idsrc="xmltag.org" >SEATTLE</location></span>, <span class="legendSpanClass"><chron>Feb. 11, 2026</chron></span> /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other areas of high unmet need, today issued a letter to Shareholders from <person value="APIN:0654458887">Steven Quay</person>, M.D., Ph.D., <span value="NASDAQ-SMALL:ATOS" idsrc="xmltag.org" >Atossa Therapeutics</span> President and Chief Executive Officer, providing an update on the Company's clinical programs and recent events. The full text of the letter follows:</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/Press+Releases/Atossa+Therapeutics+Issues+Letter+to+Shareholders+Highlighting+2025+Accomplishments+and+2026+Outlook/25980012.html Wed, 11 Feb 2026 08:30:00 -0500 A.01908724 A.06822034 A.07309385 A.18254799 ATOS O.01259980 O.11433789 O.20026344 O.20043539 O.20988509 http://www.streetinsider.com/PRNewswire/Atossa+Therapeutics+Issues+Letter+to+Shareholders+Highlighting+2025+Accomplishments+and+2026+Outlook/25980012.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.wa.seatle" idsrc="xmltag.org" >SEATTLE</location></span>, <span class="legendSpanClass"><chron>Feb. 11, 2026</chron></span> /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other areas of high unmet need, today issued a letter to Shareholders from <person value="APIN:0654458887">Steven Quay</person>, M.D., Ph.D., <span value="NASDAQ-SMALL:ATOS" idsrc="xmltag.org" >Atossa Therapeutics</span> President and Chief Executive Officer, providing an update on the Company's clinical programs and recent events. The full text of the letter follows:</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/PRNewswire/Atossa+Therapeutics+Issues+Letter+to+Shareholders+Highlighting+2025+Accomplishments+and+2026+Outlook/25980012.html Wed, 11 Feb 2026 08:30:00 -0500 A.01908724 A.06822034 A.07309385 A.18254799 ATOS O.01259980 O.11433789 O.20026344 O.20043539 O.20988509 http://www.streetinsider.com/PRNewswire/Atossa+Therapeutics+Issues+Letter+to+Shareholders+Highlighting+2025+Accomplishments+and+2026+Outlook/25980012.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.wa.seatle" idsrc="xmltag.org" >SEATTLE</location></span>, <span class="legendSpanClass"><chron>Feb. 11, 2026</chron></span> /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other areas of high unmet need, today issued a letter to Shareholders from <person value="APIN:0654458887">Steven Quay</person>, M.D., Ph.D., <span value="NASDAQ-SMALL:ATOS" idsrc="xmltag.org" >Atossa Therapeutics</span> President and Chief Executive Officer, providing an update on the Company's clinical programs and recent events. The full text of the letter follows:</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/PRNewswire/Atossa+Therapeutics+Issues+Letter+to+Shareholders+Highlighting+2025+Accomplishments+and+2026+Outlook/25980012.html Wed, 11 Feb 2026 08:30:00 -0500 A.01908724 A.06822034 A.07309385 A.18254799 ATOS O.01259980 O.11433789 O.20026344 O.20043539 O.20988509